Raymond James & Associates Aurinia Pharmaceuticals Inc. Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Raymond James & Associates holds 15,700 shares of AUPH stock, worth $113,982. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,700
Previous 17,701
11.3%
Holding current value
$113,982
Previous $88,000
1.14%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AUPH
# of Institutions
191Shares Held
56.2MCall Options Held
499KPut Options Held
637K-
Armistice Capital, LLC New York, NY11.1MShares$80.8 Million0.83% of portfolio
-
Black Rock Inc. New York, NY9.27MShares$67.3 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$28.8 Million2.14% of portfolio
-
State Street Corp Boston, MA2.88MShares$20.9 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.78MShares$20.2 Million1.94% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.03B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...